Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temanogrel in PCI for Microvascular Obstruction
NCT04848220Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of temanogrel in Microvascular obstruction (MVO), sponsored by Pfizer. Started May 2021; status: terminated.
02
Drugs
temanogrel
03
Conditions
Microvascular obstruction (MVO)
Beyond the preview
Go deeper on NCT04848220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04848220.